Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1

Recruiting

Conditions: AIDS-Related Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Biological: Pegfilgrastim
Other: Pharmacological Study
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT03220022

Locations: 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 18 locations

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Velcade
Drug: Melphalan
Drug: Prednisone
Drug: Daratumumab

First Posted Date: 2017-07-14

Last Posted Date: 2024-04-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 220

Registration Number: NCT03217812

Locations: 🇭🇰
Queen Mary Hospital University of Hong Kong, Hong Kong, Hong Kong
🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇲🇾
Hospital Ampang, Ampang, Malaysia

and more 40 locations

Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

Phase 2

Terminated

Conditions: Noninfectious Uveitis

Interventions: Drug: Placebo to match filgotinib
Drug: Filgotinib
Drug: Prednisone

First Posted Date: 2017-07-05

Last Posted Date: 2022-01-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 74

Registration Number: NCT03207815

Locations: 🇺🇸
Metropolitan Eye Research and Surgery Institute, Palisades Park, New Jersey, United States
🇺🇸
Texas Retina Associates - Fort Worth, Fort Worth, Texas, United States
🇺🇸
Colorado Retina Associates PC, Golden, Colorado, United States

and more 21 locations

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Phase 2

Completed

Conditions: Aggressive Non-Hodgkin Lymphoma

Interventions: Drug: Prednisone
Drug: Vinorelbine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2017-05-19

Last Posted Date: 2021-12-20

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 21

Registration Number: NCT03161054

Locations: 🇮🇹
A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
🇮🇹
Ospedale di Castelfranco Veneto - Ematologia, Castelfranco Veneto, Italy
🇮🇹
Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia, Reggio Emilia, Italy

and more 7 locations

Taper Or Abrupt Steroid Stop: TOASSTtrial

Phase 4

Recruiting

Conditions: Inflammatory Disorder
Autoimmune

Interventions: Other: Placebo Arm
Drug: Prednisone

First Posted Date: 2017-05-15

Last Posted Date: 2023-11-24

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 573

Registration Number: NCT03153527

Locations: 🇨🇭
Stoffwechselzentrum, Kantonsspital Olten, Olten, Switzerland
🇨🇭
Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
Departement of Internal Medicine, Kantonsspital Aarau, Aarau, Switzerland

and more 12 locations

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1

Terminated

Conditions: Solid Tumours

Interventions: Drug: GSK525762
Drug: Abiraterone
Drug: Enzalutamide
Drug: Prednisone

First Posted Date: 2017-05-11

Last Posted Date: 2022-08-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT03150056

Locations: 🇬🇧
GSK Investigational Site, Glasgow, United Kingdom

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: GnRH
Drug: Bicalutamide
Radiation: Salvage radiation
Drug: Abiraterone
Drug: Prednisone
Drug: Apalutamide

First Posted Date: 2017-05-05

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 345

Registration Number: NCT03141671

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

and more 5 locations

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Phase 3

Completed

Conditions: Graft-versus-host Disease (GVHD)

Interventions: Drug: Placebo
Drug: Itacitinib
Drug: Prednisone
Drug: Methylprednisolone

First Posted Date: 2017-05-04

Last Posted Date: 2021-08-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 439

Registration Number: NCT03139604

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸
Advocate Lutheran General Hospital - Oncology Specialists SC, Park Ridge, Illinois, United States

and more 126 locations